ReviewMolecular oncology2015
CAR T-cell immunotherapy: The path from the by-road to the freeway?
Review in Molecular oncology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed.
- Regulatory challenges of personalized medicine in the real world: are the right patients being treated with CD19-targeting CAR T-cells?EMBO molecular medicine · 2026Review
- A hybrid multiscale model for predicting CAR-T therapy outcomes in solid tumors.Scientific reports · 2026Article
- Chimeric Antigen Receptor Cell Therapy: Empowering Treatment Strategies for Solid Tumors.Current issues in molecular biology · 2025Review
- Current Insights into CAR T-Cell-Based Therapies for Myelodysplastic Syndrome.Pharmaceutical research · 2024Review
- Car T Cells in Solid Tumors: Overcoming Obstacles.International journal of molecular sciences · 2024Review
- Review
- Immunoengineering via Chimeric Antigen Receptor-T Cell Therapy: Reprogramming Nanodrug Delivery.Pharmaceutics · 2023Review
- Targeted CD7 CAR T-cells for treatment of T-Lymphocyte leukemia and lymphoma and acute myeloid leukemia: recent advances.Frontiers in immunology · 2023Review
- Mesothelin-targeting T cells bearing a novel T cell receptor fusion construct (TRuC) exhibit potent antitumor efficacy against solid tumors.Oncoimmunology · 2023Article
- Chimeric Antigen Receptor (CAR) T Cell Therapy for Glioblastoma.Cancer treatment and research · 2022Review
- Highly efficient CD4+ T cell targeting and genetic recombination using engineered CD4+ cell-homing mRNA-LNPs.Molecular therapy : the journal of the American Society of Gene Therapy · 2021Article
- CAR-T cells: Early successes in blood cancer and challenges in solid tumors.Acta pharmaceutica Sinica. B · 2021Review
- T cell circuits that sense antigen density with an ultrasensitive threshold.Science (New York, N.Y.) · 2021Article
- Preclinical Assessment of Efficacy and Safety Analysis of CAR-T Cells (ISIKOK-19) Targeting CD19-Expressing B-Cells for the First Turkish Academic Clinical Trial with Relapsed/Refractory ALL and NHL PatientsTurkish journal of haematology : official journal of Turkish Society of Haematology · 2020Article
- The Effect of Biotinylated PAMAM G3 Dendrimers Conjugated with COX-2 Inhibitor (celecoxib) and PPARγ Agonist (Fmoc-L-Leucine) on Human Normal Fibroblasts, Immortalized Keratinocytes and Glioma Cells in Vitro.Molecules (Basel, Switzerland) · 2019Article
- Article
- A method for expansion of T cells from cynomolgus monkey (Macaca fascicularis).In vitro cellular & developmental biology. Animal · 2018Article
- Strategies to Address Chimeric Antigen Receptor Tonic Signaling.Molecular cancer therapeutics · 2018Review
- Combination therapy: A feasibility strategy for CAR-T cell therapy in the treatment of solid tumors.Oncology letters · 2018Review
- The application of CAR-T cell therapy in hematological malignancies: advantages and challenges.Acta pharmaceutica Sinica. B · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Chimeric antigen receptors are genetically encoded artificial fusion molecules that can re-program the specificity of peripheral blood polyclonal T-cells against a selected cell surface target. Unparallelled clinical efficacy has recently been demonstrated using this approach to treat patients with refractory B-cell malignancy. However, the approach is technically challenging and can elicit severe toxicity in patients. Moreover, solid tumours have largely proven refractory to this approach. In this review, we describe the important structural features of CARs and how this may influence function. Emerging clinical experience is summarized in both solid tumours and haematological malignancies. Finally, we consider the particular challenges imposed by solid tumours to the successful development of CAR T-cell immunotherapy, together with a number of innovative strategies that have been developed in an effort to reverse the balance in favour of therapeutic benefit.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.